2023 Q3 Form 10-Q Financial Statement

#000186074223000021 Filed on August 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.007B $1.035B
YoY Change 6.9% 9.99%
Cost Of Revenue $392.0M $417.0M
YoY Change 5.38% 10.03%
Gross Profit $615.0M $618.0M
YoY Change 7.89% 9.96%
Gross Profit Margin 61.07% 59.71%
Selling, General & Admin $418.0M $399.0M
YoY Change 9.71% 8.42%
% of Gross Profit 67.97% 64.56%
Research & Development $82.00M $85.00M
YoY Change 6.49% 13.33%
% of Gross Profit 13.33% 13.75%
Depreciation & Amortization $82.00M $56.00M
YoY Change -11.83% -42.86%
% of Gross Profit 13.33% 9.06%
Operating Expenses $500.0M $540.0M
YoY Change 9.17% 21.9%
Operating Profit $40.00M $78.00M
YoY Change -13.04% 39.29%
Interest Expense -$75.00M -$62.00M
YoY Change 177.78% 113.79%
% of Operating Profit -187.5% -79.49%
Other Income/Expense, Net -$28.00M -$17.00M
YoY Change 300.0% -1800.0%
Pretax Income -$35.00M -$19.00M
YoY Change -284.21% -170.37%
Income Tax $45.00M $10.00M
% Of Pretax Income
Net Earnings -$84.00M -$32.00M
YoY Change 366.67% -740.0%
Net Earnings / Revenue -8.34% -3.09%
Basic Earnings Per Share -$0.24 -$0.09
Diluted Earnings Per Share -$0.24 -$0.09
COMMON SHARES
Basic Shares Outstanding 350.7M shares 350.3M shares
Diluted Shares Outstanding 350.8M shares 350.5M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $355.0M $384.0M
YoY Change 23.69% -12.13%
Cash & Equivalents $355.0M $384.0M
Short-Term Investments
Other Short-Term Assets $572.0M $441.0M
YoY Change 102.84% 55.28%
Inventory $754.0M $699.0M
Prepaid Expenses
Receivables $783.0M $791.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.464B $2.315B
YoY Change 32.54% 15.69%
LONG-TERM ASSETS
Property, Plant & Equipment $1.284B $1.294B
YoY Change 5.07% 4.1%
Goodwill $4.526B $4.540B
YoY Change 2.51% 1.05%
Intangibles $3.662B $2.021B
YoY Change 77.08% -5.16%
Long-Term Investments
YoY Change
Other Assets $212.0M $207.0M
YoY Change -7.02% -6.76%
Total Long-Term Assets $10.60B $9.000B
YoY Change 20.0% -0.01%
TOTAL ASSETS
Total Short-Term Assets $2.464B $2.315B
Total Long-Term Assets $10.60B $9.000B
Total Assets $13.07B $11.32B
YoY Change 22.18% 2.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $364.0M $348.0M
YoY Change 23.39% -2.52%
Accrued Expenses $992.0M $952.0M
YoY Change 12.86% 6.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $30.00M $25.00M
YoY Change 20.0% 0.0%
Total Short-Term Liabilities $1.386B $1.325B
YoY Change 15.6% 4.08%
LONG-TERM LIABILITIES
Long-Term Debt $4.435B $2.604B
YoY Change 83.8% 7.74%
Other Long-Term Liabilities $353.0M $342.0M
YoY Change 26.52% 3.32%
Total Long-Term Liabilities $4.788B $2.946B
YoY Change 77.86% 7.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.386B $1.325B
Total Long-Term Liabilities $4.788B $2.946B
Total Liabilities $6.185B $4.285B
YoY Change 58.55% 6.3%
SHAREHOLDERS EQUITY
Retained Earnings -$200.0M -$116.0M
YoY Change -2957.14% -564.0%
Common Stock $8.334B $8.321B
YoY Change 2.79% 2.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.817B $6.958B
YoY Change
Total Liabilities & Shareholders Equity $13.07B $11.32B
YoY Change 22.18% 2.84%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$84.00M -$32.00M
YoY Change 366.67% -740.0%
Depreciation, Depletion And Amortization $82.00M $56.00M
YoY Change -11.83% -42.86%
Cash From Operating Activities $48.00M -$24.00M
YoY Change 77.78% -115.38%
INVESTING ACTIVITIES
Capital Expenditures $33.00M $27.00M
YoY Change -167.35% -179.41%
Acquisitions
YoY Change
Other Investing Activities -$1.849B -$1.000M
YoY Change 0.0%
Cash From Investing Activities -$1.882B -$28.00M
YoY Change 3740.82% -20.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.811B 90.00M
YoY Change -1761.47% -37.93%
NET CHANGE
Cash From Operating Activities 48.00M -24.00M
Cash From Investing Activities -1.882B -28.00M
Cash From Financing Activities 1.811B 90.00M
Net Change In Cash -23.00M 38.00M
YoY Change -82.44% -85.71%
FREE CASH FLOW
Cash From Operating Activities $48.00M -$24.00M
Capital Expenditures $33.00M $27.00M
Free Cash Flow $15.00M -$51.00M
YoY Change -80.26% -126.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
350000000 shares
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-29000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7030000000 usd
CY2022Q2 blco Adjustments To Additional Paid In Capital Distributions To Affiliates
AdjustmentsToAdditionalPaidInCapitalDistributionsToAffiliates
-142000000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
7000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-121000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6971000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7101000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42000000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7030000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9402000000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
blco Net Parent Investment Decrease In Conjunction With Legal Reorganization
NetParentInvestmentDecreaseInConjunctionWithLegalReorganization
2200000000 usd
blco Adjustments To Additional Paid In Capital Distributions To Affiliates
AdjustmentsToAdditionalPaidInCapitalDistributionsToAffiliates
-87000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000000 usd
us-gaap Profit Loss
ProfitLoss
30000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6971000000 usd
us-gaap Profit Loss
ProfitLoss
-117000000 usd
us-gaap Profit Loss
ProfitLoss
30000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
184000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
193000000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6000000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2000000 usd
blco Allowances For Losses On Accounts Receivable And Inventories
AllowancesForLossesOnAccountsReceivableAndInventories
10000000 usd
blco Allowances For Losses On Accounts Receivable And Inventories
AllowancesForLossesOnAccountsReceivableAndInventories
8000000 usd
blco Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-19000000 usd
blco Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-41000000 usd
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
0 usd
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
3000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
42000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
27000000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-9000000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
6000000 usd
blco Derivative Gain Excluded Component
DerivativeGainExcludedComponent
6000000 usd
blco Derivative Gain Excluded Component
DerivativeGainExcludedComponent
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3000000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
1000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 usd
us-gaap Proceeds From Derivative Instrument Investing Activities
ProceedsFromDerivativeInstrumentInvestingActivities
6000000 usd
us-gaap Proceeds From Derivative Instrument Investing Activities
ProceedsFromDerivativeInstrumentInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2440000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
13000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3000000 usd
blco Net Borrowings Financing Activities
NetBorrowingsFinancingActivities
0 usd
blco Net Borrowings Financing Activities
NetBorrowingsFinancingActivities
31000000 usd
blco Net Transfers Financing Activities
NetTransfersFinancingActivities
0 usd
blco Net Transfers Financing Activities
NetTransfersFinancingActivities
2271000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
197000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
269000000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
392000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
446000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
26000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000000 usd
us-gaap Notes Issued1
NotesIssued1
0 usd
us-gaap Notes Issued1
NotesIssued1
2200000000 usd
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. The Company operates in three reportable segments: (i) Vision Care segment which includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter (“OTC”) eye drops and eye vitamins, (ii) Pharmaceuticals segment which consists of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases and (iii) Surgical segment which consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes intraocular lenses (“IOLs”) and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Effective June 30, 2023, the Company renamed its former Ophthalmic Pharmaceuticals segment to the Pharmaceuticals segment. Aside from the change in name, there were no other changes made to this segment. See Note 18, “SEGMENT INFORMATION” for additional information regarding these reportable segments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC holding, directly or indirectly, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.5%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the issued and outstanding common shares of Bausch + Lomb as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 28, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Separation of Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, BHC announced its plan to separate Bausch + Lomb into an independent, publicly traded company, separate from the remainder of BHC (the “Separation”), commencing with an initial public offering of Bausch + Lomb's common shares (as further described below). Prior to January 1, 2022, Bausch + Lomb had nominal assets and liabilities. In connection with the B+L IPO (as defined below), BHC transferred to Bausch + Lomb, in a series of steps, all the entities, assets, liabilities and obligations that Bausch + Lomb held upon completion of the B+L IPO pursuant to a Master Separation Agreement (the “MSA”) with BHC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement related to the initial public offering (the “IPO”) of Bausch + Lomb’s common shares (the “B+L IPO”) was declared effective on May 5, 2022, and Bausch + Lomb’s common shares began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol “BLCO”, on May 6, 2022. Bausch + Lomb also obtained a final receipt to its Canadian base PREP prospectus on May 5, 2022. Prior to the B+L IPO, Bausch + Lomb was a wholly-owned subsidiary of BHC. On May 10, 2022, a wholly-owned subsidiary of BHC (the “Selling Shareholder”) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share (less the applicable underwriting discount), pursuant to the Bausch + Lomb prospectuses. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters for the B+L IPO partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less the applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired. The Selling Shareholder received all net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters. As of July 28, 2023, BHC directly or indirectly held 310,449,643 common shares of Bausch + Lomb, which represented approximately 88.5% of the issued and outstanding common shares of Bausch + Lomb. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the full Separation of Bausch + Lomb, which includes the transfer of all or a portion of BHC’s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the “Distribution”), is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals and other factors and is subject to various risk factors relating to the Separation. See Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (“CSA”) on February 22, 2023 (the “Annual Report”) for additional information on the risks associated with the Separation. Bausch + Lomb understands that BHC continues to believe that completing the B+L Separation makes strategic sense and that BHC continues to evaluate all relevant factors and considerations related to completing the Separation, including the effect of the lawsuit filed against Norwich Pharmaceuticals Inc.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company’s Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that certain global macroeconomic conditions, including, but not limited to, those related to the COVID-19 pandemic and other macroeconomic factors, including those related to inflation and supply chain, will have on the Company's operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of finite-lived intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants, reporting unit fair values for testing goodwill for impairment; acquisition-related contingent consideration liabilities; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; the fair value of cross-currency swaps; and the fair value of foreign currency exchange contracts. Prior to the B+L IPO, significant estimates made by management also included the related allocations described in the basis of presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All estimates in these Condensed Consolidated Financial Statements are based on assumptions that management believes are reasonable. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company's business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company's business, financial condition, cash flows and results of operations could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which certain global macroeconomic conditions, including, but not limited to, those related to the COVID-19 pandemic and its overall impact on inflation and supply chain, may continue to impact the Company’s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company’s control. The Company has assessed the possible effects and outcomes of these macroeconomic conditions on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable.</span></div>
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
484000000 usd
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
775000000 usd
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
784000000 usd
CY2023Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
475000000 usd
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
468000000 usd
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
687000000 usd
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
598000000 usd
CY2022Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
557000000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
22000000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
16000000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2000000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1000000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1000000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1000000 usd
blco Accounts Receivable Allowance For Foreign Exchange And Other
AccountsReceivableAllowanceForForeignExchangeAndOther
-1000000 usd
blco Accounts Receivable Allowance For Foreign Exchange And Other
AccountsReceivableAllowanceForForeignExchangeAndOther
2000000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
22000000 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
18000000 usd
CY2022Q4 blco Related Party Net Borrowings
RelatedPartyNetBorrowings
0 usd
CY2023Q2 blco Related Party Cash Pooling And General Financing Activities
RelatedPartyCashPoolingAndGeneralFinancingActivities
0 usd
CY2022Q2 blco Related Party Cash Pooling And General Financing Activities
RelatedPartyCashPoolingAndGeneralFinancingActivities
-142000000 usd
blco Related Party Cash Pooling And General Financing Activities
RelatedPartyCashPoolingAndGeneralFinancingActivities
0 usd
blco Related Party Cash Pooling And General Financing Activities
RelatedPartyCashPoolingAndGeneralFinancingActivities
-229000000 usd
CY2023Q2 blco Related Party Corporate Allocations
RelatedPartyCorporateAllocations
0 usd
CY2022Q2 blco Related Party Corporate Allocations
RelatedPartyCorporateAllocations
0 usd
blco Related Party Corporate Allocations
RelatedPartyCorporateAllocations
0 usd
blco Related Party Corporate Allocations
RelatedPartyCorporateAllocations
76000000 usd
CY2023Q2 blco Related Party Benefit From Income Taxes
RelatedPartyBenefitFromIncomeTaxes
0 usd
CY2022Q2 blco Related Party Benefit From Income Taxes
RelatedPartyBenefitFromIncomeTaxes
0 usd
blco Related Party Benefit From Income Taxes
RelatedPartyBenefitFromIncomeTaxes
0 usd
blco Related Party Benefit From Income Taxes
RelatedPartyBenefitFromIncomeTaxes
66000000 usd
CY2023Q2 blco Related Party Total Net Transfers
RelatedPartyTotalNetTransfers
0 usd
CY2022Q2 blco Related Party Total Net Transfers
RelatedPartyTotalNetTransfers
-142000000 usd
blco Related Party Total Net Transfers
RelatedPartyTotalNetTransfers
0 usd
blco Related Party Total Net Transfers
RelatedPartyTotalNetTransfers
-87000000 usd
blco Related Party Payment Of Purchase Debt
RelatedPartyPaymentOfPurchaseDebt
0 usd
blco Related Party Payment Of Purchase Debt
RelatedPartyPaymentOfPurchaseDebt
2200000000 usd
blco Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense
RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense
0 usd
blco Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense
RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense
16000000 usd
blco Related Party Net Transfers Other
RelatedPartyNetTransfersOther
0 usd
blco Related Party Net Transfers Other
RelatedPartyNetTransfersOther
-32000000 usd
blco Net Transfers Financing Activities
NetTransfersFinancingActivities
0 usd
blco Net Transfers Financing Activities
NetTransfersFinancingActivities
2271000000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4000000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
9000000 usd
blco Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
Acquisition-related contingent consideration adjustments
blco Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
Acquisition-related contingent consideration adjustments
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-5000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
5000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10000000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4000000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4000000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6000000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4000000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
191000000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
163000000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
55000000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
44000000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
453000000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
421000000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
699000000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
628000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3798000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3475000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
323000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3720000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3360000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
360000000 usd
CY2023Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5496000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3475000000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2021000000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5418000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3360000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2058000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
77000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
97000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
51000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
18000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
17000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
17000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
46000000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
323000000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
4586000000 usd
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5000000 usd
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
84000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4507000000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
8000000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-25000000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
4540000000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
191000000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
196000000 usd
CY2023Q2 blco Accrued Product Rebates Current
AccruedProductRebatesCurrent
145000000 usd
CY2022Q4 blco Accrued Product Rebates Current
AccruedProductRebatesCurrent
153000000 usd
CY2023Q2 blco Accrued Discounts And Allowances Current
AccruedDiscountsAndAllowancesCurrent
82000000 usd
CY2022Q4 blco Accrued Discounts And Allowances Current
AccruedDiscountsAndAllowancesCurrent
85000000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70000000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
66000000 usd
CY2023Q2 blco Accrued Product Returns Current
AccruedProductReturnsCurrent
63000000 usd
CY2022Q4 blco Accrued Product Returns Current
AccruedProductReturnsCurrent
59000000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
401000000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
342000000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
952000000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
901000000 usd
CY2023Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.0851
CY2022Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.0784
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3130000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6455000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.16
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.55
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
111000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q2 blco Research And Development Expense Product Related
ResearchAndDevelopmentExpenseProductRelated
79000000 usd
CY2022Q2 blco Research And Development Expense Product Related
ResearchAndDevelopmentExpenseProductRelated
69000000 usd
blco Research And Development Expense Product Related
ResearchAndDevelopmentExpenseProductRelated
151000000 usd
blco Research And Development Expense Product Related
ResearchAndDevelopmentExpenseProductRelated
141000000 usd
CY2023Q2 blco Research And Development Expense Quality Assurance
ResearchAndDevelopmentExpenseQualityAssurance
6000000 usd
CY2022Q2 blco Research And Development Expense Quality Assurance
ResearchAndDevelopmentExpenseQualityAssurance
6000000 usd
blco Research And Development Expense Quality Assurance
ResearchAndDevelopmentExpenseQualityAssurance
11000000 usd
blco Research And Development Expense Quality Assurance
ResearchAndDevelopmentExpenseQualityAssurance
11000000 usd
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
85000000 usd
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
75000000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
162000000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
152000000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
14000000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
4000000 usd
us-gaap Restructuring Charges
RestructuringCharges
22000000 usd
us-gaap Restructuring Charges
RestructuringCharges
6000000 usd
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2000000 usd
CY2022Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
3000000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1000000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5000000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1000000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5000000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000000 usd
us-gaap Severance Costs1
SeveranceCosts1
22000000 usd
us-gaap Severance Costs1
SeveranceCosts1
3000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000000 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
132000000 usd
CY2023Q2 blco Unrecognized Tax Benefits Including Interest And Penalties
UnrecognizedTaxBenefitsIncludingInterestAndPenalties
70000000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
10000000 usd
CY2023Q2 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
62000000 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
350000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
350000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350500000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350000000.0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
350300000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350300000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
350000000.0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
350000000.0 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
4000000 usd
CY2023Q2 blco Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold
AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
56000000 usd
CY2022Q2 blco Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold
AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
64000000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-17000000 usd
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
43000000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
56000000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000000 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
58000000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
44000000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000000 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
14000000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19000000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27000000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1035000000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
941000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1966000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1830000000 usd
blco Concentration Risk Number Of Products Franchises
ConcentrationRiskNumberOfProductsFranchises
10 product
blco Concentration Risk Number Of Products Franchises
ConcentrationRiskNumberOfProductsFranchises
10 product
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1966000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1830000000 usd

Files In Submission

Name View Source Status
0001860742-23-000021-index-headers.html Edgar Link pending
0001860742-23-000021-index.html Edgar Link pending
0001860742-23-000021.txt Edgar Link pending
0001860742-23-000021-xbrl.zip Edgar Link pending
blco-20230630.htm Edgar Link pending
blco-20230630.xsd Edgar Link pending
exhibit101-employmentagree.htm Edgar Link pending
exhibit311q22023.htm Edgar Link pending
exhibit312q22023.htm Edgar Link pending
exhibit321q22023.htm Edgar Link pending
exhibit322q22023.htm Edgar Link pending
exhibit41-descriptionofsec.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
blco-20230630_def.xml Edgar Link unprocessable
blco-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blco-20230630_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blco-20230630_cal.xml Edgar Link unprocessable
blco-20230630_pre.xml Edgar Link unprocessable